This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical ...
Key market opportunities include the rising demand for AI-enhanced trial design, boosted by increasing complexity in clinical ...
A deep learning platform may help predict how people with advanced lung cancer will respond to immunotherapy, according to ...
The field of cancer immunotherapy and immunology is rapidly reshaping modern oncology, yet the translational gap between mechanistic discoveries and durable ...
PITTSBURGH, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced that it has expanded the available applications for its ...
Certis Oncology, an AI-enabled translational science company, today announced the launch of Certis Oncology Intelligence ®, an integrated platform designed to generate data-driven insights into ...
PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response data ...
We analyzed a prospective multi-institutional cohort of 278 patients treated from 2012 to 2023 across 10 centers. Dosimetric and nondosimetric variables were collected, and key predictors were ...
EAGAN, Minn., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results